Xunshuai Zhu

Nanning, 530021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Retraction notice to "Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression" [Int. Immunopharmacol. 42 (2017) 130-138].

Retraction notice to "Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression" [Int. Immunopharmacol. 42 (2017) 130-138].

Journal: International immunopharmacology

Published: September 09, 2025

[Retracted] Inhibition of RKIP aggravates thioacetamide‑induced acute liver failure in mice.

[Retracted] Inhibition of RKIP aggravates thioacetamide‑induced acute liver failure in mice.

Journal: Experimental and therapeutic medicine

Published: May 25, 2023

Corrigendum to "4-Hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice" [Int. Immunopharmacol. 83 (2020) 106445].

Corrigendum to "4-Hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice" [Int. Immunopharmacol. 83 (2020) 106445].

Journal: International immunopharmacology

Published: June 29, 2020

4-hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice.

4-hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice.

Journal: International immunopharmacology

Published: November 05, 2019

HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways.

HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 13, 2019

Trolline Ameliorates Liver Fibrosis by Inhibiting the NF-κB Pathway, Promoting HSC Apoptosis and Suppressing Autophagy.

Trolline Ameliorates Liver Fibrosis by Inhibiting the NF-κB Pathway, Promoting HSC Apoptosis and Suppressing Autophagy.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: May 24, 2017

Didymin Alleviates Hepatic Fibrosis Through Inhibiting ERK and PI3K/Akt Pathways via Regulation of Raf Kinase Inhibitor Protein.

Didymin Alleviates Hepatic Fibrosis Through Inhibiting ERK and PI3K/Akt Pathways via Regulation of Raf Kinase Inhibitor Protein.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: November 21, 2016

Inhibition of RKIP aggravates thioacetamide-induced acute liver failure in mice.

Inhibition of RKIP aggravates thioacetamide-induced acute liver failure in mice.

Journal: Experimental and therapeutic medicine

Published: October 06, 2016

Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression.

Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression.

Journal: International immunopharmacology

Published: August 30, 2016

Showing 1-9 of 9

Last Updated: 09/26/2026